YU47902A - Novi polimorfi sertralin hidrohlorida, postupci za njihovo dobijanje, preparati koji ih sadrže i postupci za njihovu upotrebu - Google Patents

Novi polimorfi sertralin hidrohlorida, postupci za njihovo dobijanje, preparati koji ih sadrže i postupci za njihovu upotrebu

Info

Publication number
YU47902A
YU47902A YU47902A YUP47902A YU47902A YU 47902 A YU47902 A YU 47902A YU 47902 A YU47902 A YU 47902A YU P47902 A YUP47902 A YU P47902A YU 47902 A YU47902 A YU 47902A
Authority
YU
Yugoslavia
Prior art keywords
methods
preparing
processes
sertraline hydrochloride
compositions containing
Prior art date
Application number
YU47902A
Other languages
English (en)
Inventor
Judith Aronhime
Marioana Mendelovici
Tamar Nidam
Claude Singer
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of YU47902A publication Critical patent/YU47902A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Predmetni pronalazak se odnosi na nove polimorfne Oblike XI, XII, XIII, XIV, XV i XVI sertralin hidrohlorida, postupke njihovog dobijanja, postupke njihovog korišćenja u lečenju bolesti, postupke njihovog korišenja za dobijanje drugih oblika sertralin hidrohlorida, i farmaceutske oblike za doziranje koji sadrže ove nove oblike.[The present invention is directed to novel polymorphic Forms XI, XII, XIII, XIV, XV and XVI of sertraline hydrochloride, to processes for preparing them, methods of using them to treat disease, methods of using them to make other sertraline hydrochloride forms, and to pharmaceutical dosages containing the novel forms.
YU47902A 1999-12-21 2000-12-21 Novi polimorfi sertralin hidrohlorida, postupci za njihovo dobijanje, preparati koji ih sadrže i postupci za njihovu upotrebu YU47902A (sh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17134199P 1999-12-21 1999-12-21
US18733600P 2000-03-06 2000-03-06
US18791000P 2000-03-08 2000-03-08
US19060300P 2000-03-20 2000-03-20

Publications (1)

Publication Number Publication Date
YU47902A true YU47902A (sh) 2005-11-28

Family

ID=27496950

Family Applications (1)

Application Number Title Priority Date Filing Date
YU47902A YU47902A (sh) 1999-12-21 2000-12-21 Novi polimorfi sertralin hidrohlorida, postupci za njihovo dobijanje, preparati koji ih sadrže i postupci za njihovu upotrebu

Country Status (19)

Country Link
US (2) US6452054B2 (sh)
EP (2) EP1797875A3 (sh)
JP (2) JP4057295B2 (sh)
KR (1) KR100791872B1 (sh)
CN (1) CN1434708A (sh)
AT (1) ATE354358T1 (sh)
AU (1) AU780771B2 (sh)
DE (1) DE60033566T2 (sh)
DK (1) DK1248605T3 (sh)
ES (1) ES2281374T3 (sh)
HR (1) HRP20020543A2 (sh)
HU (1) HUP0204010A3 (sh)
IL (1) IL150332A0 (sh)
IS (1) IS6425A (sh)
PL (1) PL356452A1 (sh)
PT (1) PT1248605E (sh)
SK (1) SK8872002A3 (sh)
WO (1) WO2001045692A1 (sh)
YU (1) YU47902A (sh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6978342B1 (en) 1995-07-31 2005-12-20 Lexar Media, Inc. Moving sectors within a block of information in a flash memory mass storage architecture
US5845313A (en) 1995-07-31 1998-12-01 Lexar Direct logical block addressing flash memory mass storage architecture
US6500987B1 (en) 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6495721B1 (en) * 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
TWI260315B (en) 1999-10-29 2006-08-21 Ciba Sc Holding Ag Polymorphic forms of sertraline hydrochloride
PL356452A1 (en) 1999-12-21 2004-06-28 Teva Pharmaceutical Industries Ltd. Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
IL151691A0 (en) * 2000-03-14 2003-04-10 Teva Pharma Novel process for preparing (+)-cis-sertraline
EP1397342A1 (en) * 2001-05-31 2004-03-17 Orion Corporation Fermion Process for preparing sertraline intermediates
WO2002096859A1 (en) * 2001-05-31 2002-12-05 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
GB0123421D0 (en) 2001-09-28 2001-11-21 Memquest Ltd Power management system
WO2003093217A1 (en) 2002-04-29 2003-11-13 Teva Pharmaceutical Industries Ltd. Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20040131672A1 (en) * 2003-01-07 2004-07-08 Nilobon Podhipleux Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
WO2005000786A1 (en) * 2003-05-23 2005-01-06 Transform Pharmaceuticals, Inc. Sertraline compositions
CA2537804A1 (en) * 2003-09-05 2005-03-17 Teva Pharmaceutical Industries Ltd A recycling process for preparing sertraline
JP4791970B2 (ja) * 2003-11-04 2011-10-12 シプラ・リミテッド 選択的セロトニン再取込み阻害剤の多形体の製造方法
US7464306B1 (en) 2004-08-27 2008-12-09 Lexar Media, Inc. Status of overall health of nonvolatile memory
US7345201B2 (en) * 2005-02-23 2008-03-18 Teva Pharmaceutical Industries, Ltd. Processes for preparing sertraline
WO2006103506A1 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Sertraline-containing pharmaceutical compositions and a process for preparation thereof
GB0507090D0 (en) * 2005-04-07 2005-05-11 Sandoz Ag Process for preparing polymorphic form ll of sertraline hydrochloride
US7518019B2 (en) * 2006-06-01 2009-04-14 Hetero Drugs Limited Processes for preparing sertraline hydrochloride crystalline forms
US20060257475A1 (en) * 2006-08-17 2006-11-16 Boehringer Ingelheim International Gmbh Stable Sertraline Hydrochloride Formulation and Method
CA2594198A1 (en) * 2007-07-20 2009-01-20 Apotex Pharmachem Inc. A novel process for the preparation of sertraline hydrochloride form ii
FR2928148B1 (fr) * 2008-02-28 2013-01-18 Sanofi Aventis Procede de preparation de combretastatine
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US5082970A (en) 1991-03-06 1992-01-21 Pfizer Inc. Process for recycling amine isomer
GB9114947D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5734083A (en) * 1996-05-17 1998-03-31 Torcan Chemical Ltd. Sertraline polymorph
ES2217748T3 (es) 1998-03-18 2004-11-01 Ciba Specialty Chemicals Holding Inc. Procedimiento para la hidrogenacin catalitica cis-selectiva de ciclohexilidenaminas.
JP2000026379A (ja) * 1998-07-08 2000-01-25 Sumika Fine Chemicals Co Ltd 塩酸セルトラリンメタノール和物および塩酸セルトラリンエタノール和物、ならびにそれらの製法
US6500987B1 (en) 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
JP2002531427A (ja) * 1998-11-27 2002-09-24 テバ ファーマシューティカル インダストリーズ リミティド セルトラリン塩酸塩多形体
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
TWI260315B (en) * 1999-10-29 2006-08-21 Ciba Sc Holding Ag Polymorphic forms of sertraline hydrochloride
PL356452A1 (en) * 1999-12-21 2004-06-28 Teva Pharmaceutical Industries Ltd. Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
IN192343B (sh) 2000-05-26 2004-04-10 Ranbaxy Lab Ltd

Also Published As

Publication number Publication date
JP2003518056A (ja) 2003-06-03
CN1434708A (zh) 2003-08-06
PT1248605E (pt) 2007-03-30
HRP20020543A2 (en) 2005-04-30
ATE354358T1 (de) 2007-03-15
WO2001045692A9 (en) 2002-07-04
DK1248605T3 (da) 2007-03-19
US20030023117A1 (en) 2003-01-30
IS6425A (is) 2002-06-18
KR100791872B1 (ko) 2008-01-07
PL356452A1 (en) 2004-06-28
ES2281374T3 (es) 2007-10-01
JP4057295B2 (ja) 2008-03-05
WO2001045692A1 (en) 2001-06-28
JP2007308505A (ja) 2007-11-29
HUP0204010A2 (hu) 2003-04-28
EP1248605A4 (en) 2004-11-24
DE60033566D1 (de) 2007-04-05
IL150332A0 (en) 2002-12-01
AU2737601A (en) 2001-07-03
AU780771B2 (en) 2005-04-14
KR20020062356A (ko) 2002-07-25
EP1248605A2 (en) 2002-10-16
SK8872002A3 (en) 2002-12-03
EP1797875A2 (en) 2007-06-20
HUP0204010A3 (en) 2006-02-28
EP1248605B1 (en) 2007-02-21
EP1797875A3 (en) 2007-08-29
US20010041815A1 (en) 2001-11-15
DE60033566T2 (de) 2007-10-25
US6858652B2 (en) 2005-02-22
US6452054B2 (en) 2002-09-17

Similar Documents

Publication Publication Date Title
YU47902A (sh) Novi polimorfi sertralin hidrohlorida, postupci za njihovo dobijanje, preparati koji ih sadrže i postupci za njihovu upotrebu
YU56995A (sh) Soli derivata indola
BR0113234A (pt) Polimorfos de um análogo de epotilona
WO2002085925A3 (en) Melanocortin receptor ligands
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
IL160045A0 (en) Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
GC0000375A (en) Benzodiazepine derivatives as gaba a receptor modulators
DE60022230D1 (de) Verfahren zur herstllung von clarithromycin polymorphen und polymorph iv
DE60226044D1 (de) Kristalline formen von fluvastatin-natrium
BG105197A (en) Polymorph form of a medicament
BG101605A (bg) Ентерокинетични бензамиди
UA66866C2 (uk) Синтез морфолінових похідних
NO308658B1 (no) Sammenføyde isoquinoliner som dopamin-reseptor-ligander
TR199901761T2 (xx) IL-8 resept�r antagonistleri.
TR200503401T1 (tr) Kuetiapin (Quetiapine) Fumarat'ın yeni polimorfları
YU37597A (sh) Novi derivati piranozida
PT1206452E (pt) Processo de preparacao de compostos benzoper-hidroisoindole
EP1772144A3 (en) Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
YU22797A (sh) Postupak i intermedijarna jedinjenja za dobijanje pesticidnih fluoroolefinskih jedinjenja
NZ320522A (en) Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same and a process for the preparation of the compounds
DK1000067T3 (da) Thiazolobenzoheterocycliske forbindelser, deres fremstilling og lægemidler indeholdende forbindelserne
MA28213A1 (fr) Derives de bengamide, procede de production de ceux-ci et leur utilisation pour le traitement du cancer
NO20031137D0 (no) Fremgangsmåte for fremstilling av kirale forbindelser
BG104964A (bg) Подобрен метод за получаване на фармацевтично ценни норбензоморфанови производни